Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies has concluded a 12-month follow-up study on 2,449 subjects recruited in a Phase 3 study of Heplisav evaluating immunogenicity in comparison to Engerix.
Subscribe to our email newsletter
The company expects to disclose the results within eight weeks.
Heplisav is an experimental adult hepatitis B vaccine which is evaluated in two Phase 3 studies that are directed toward fulfilling licensure requirements in the US, Canada and Europe.
In the previous Phase 3 trial, Heplisav showed increased protection with fewer doses than current licensed vaccines.
Heplisav combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.